Want to see ECIA full AI Analyst Report?
Top Page
Encision
(OTC:ECIA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.18
▲(31.43% Upside)
Action:Upgraded
Date:08/27/26
The score is primarily weighed down by weak financial performance (declining revenue, widening losses, negative operating/free cash flow, and rising leverage). Technical indicators show potentially oversold conditions (low RSI/Stochastics) but with bearish MACD, offering only limited support. Valuation is also a headwind due to negative earnings (negative P/E) and no dividend yield provided.
Positive Factors
Recurring Disposable Product Demand
A procedure-driven disposable model can create repeat purchasing from hospitals and surgical centers. If surgical volumes and product adoption remain stable, recurring component usage provides a durable revenue foundation and supports customer retention.
Negative Factors
Persistent Revenue Contraction
Multi-year revenue contraction signals weakening demand, limited market expansion, or competitive pressure in the company’s surgical product base. Continued shrinkage reduces scale, makes fixed costs harder to absorb, and limits the prospect of sustainable operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Disposable Product Demand
A procedure-driven disposable model can create repeat purchasing from hospitals and surgical centers. If surgical volumes and product adoption remain stable, recurring component usage provides a durable revenue foundation and supports customer retention.
Read all positive factors
Encision (ECIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.21M
Dividend YieldN/A
Average Volume (3M)16.18K
Price to Earnings (P/E)―
Beta (1Y)23.07
Revenue Growth-2.97%
EPS Growth56.17%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.02
Shares Outstanding16,879,644
10 Day Avg. Volume10,380
30 Day Avg. Volume16,177
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.35
Price to Sales (P/S)0.33
P/FCF Ratio-4.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Encision Business Overview & Revenue Model
Company Description
Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The ...
How the Company Makes Money
Encision generated revenue primarily by selling its surgical device products to hospitals and surgical centers for use during procedures. The company’s business model relied on recurring sales of disposable, single-use components consumed per proc...
Encision Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
40
Negative
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.74M | 5.78M | 6.56M | 6.59M | 7.35M | 7.67M |
| Gross Profit | 1.29M | 2.71M | 3.51M | 3.14M | 4.03M | 3.79M |
| EBITDA | -177.75K | -542.60K | -95.08K | -544.20K | -217.51K | 55.10K |
| Net Income | -243.57K | -719.08K | -220.20K | -691.78K | -366.00K | 463.34K |
Balance Sheet | ||||||
| Total Assets | 3.51M | 3.70M | 3.67M | 3.81M | 4.13M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 170.76K | 245.11K | 257.43K | 42.51K | 189.00K | 950.00K |
| Total Debt | 1.56M | 1.70M | 1.31M | 1.33M | 1.08M | 1.15M |
| Total Liabilities | 2.05M | 2.27M | 2.02M | 1.98M | 1.64M | 2.05M |
| Stockholders Equity | 1.46M | 1.43M | 1.65M | 1.83M | 2.50M | 2.75M |
Cash Flow | ||||||
| Free Cash Flow | 51.41K | -427.64K | -134.97K | 107.57K | -1.04M | -480.00K |
| Operating Cash Flow | 37.28K | -384.42K | -54.95K | 144.39K | -861.00K | -444.00K |
| Investing Cash Flow | -42.99K | -45.62K | -80.03K | -36.82K | -183.00K | -36.00K |
| Financing Cash Flow | -109.08K | 417.72K | 349.90K | -254.02K | 284.00K | -44.00K |
Encision Technical Analysis
Positive
0.14
Price Trends
0.10
Positive
0.13
Positive
0.17
Positive
Market Momentum
>-0.01
Negative
77.33
Negative
33.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECIA, the sentiment is Positive. The current price of 0.14 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.10, and below the 200-day MA of 0.17, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 77.33 is Negative, neither overbought nor oversold. The STOCH value of 33.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ECIA.
Encision Risk Analysis
Encision disclosed 14 risk factors in its most recent earnings report. Encision reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Encision Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $9.73M | -0.70 | -83.38% | ― | 72.50% | 58.34% | |
45 Neutral | $3.21M | -7.60 | -21.36% | ― | -2.97% | 56.17% | |
43 Neutral | $5.66M | -0.01 | -6.86% | ― | ― | ― | |
42 Neutral | $3.40M | -0.02 | -581.98% | ― | ― | 99.51% |
* Healthcare Sector Average
ECIA
Encision
0.19
-0.21
-52.75%
GCTK
GlucoTrack
0.29
-3.93
-93.22%
LUCY
Innovative Eyewear, Inc.
0.94
-0.99
-51.24%
WOK
WORK Medical Technology Group LTD
2.35
-787,797.65
-100.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.